Comprehensive genomic profiling service for haematological malignancies and sarcomas; to guide diagnosis, prognosis and treatment selection and personalise patients' treatment plans.1-3
This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as the licensed distributor of Foundation Medicine products outside of the US.
Please select an option:
Please note that you are now leaving www.foundationmedicine.my
"Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.
†Peripheral blood and bone marrow aspirate must be received the day after collection for optimal analysis as sensitivity of detection may degrade with time. Samples arriving later will result in a Qualified Report. FFPE block or slides are also accepted.
GIST, gastrointestinal stromal tumours. FFPE, formalin-fixed paraffin-embedded. MSI, microsatellite instability. RMS, rhabdomyosarcoma. TMB, tumour mutational burden.